CAPTRUST Financial Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Buy	11,845 +1,089	+10%	+$14.9K	﹤0.01%	2872
2026 Q1	$134K	Buy	+10,756	New	+$144K	﹤0.01%	2764
2025 Q4	–	Sell	-12,048	Closed	-$121K	–	2742
2025 Q3	$121K	Buy	+12,048	New	+$108K	﹤0.01%	2492
2022 Q3	–	Sell	-20,855	Closed	-$66K	–	2142
2022 Q2	$66K	Sell	20,855 -34,966	-63%	-$127K	﹤0.01%	2524
2022 Q1	$233K	Buy	55,821 +55,581	+23,159%	+$246K	﹤0.01%	1616
2021 Q4	$1K	Sell	240 -83	-26%	-$414	﹤0.01%	4527
2021 Q3	$2K	Hold	323	–	–	﹤0.01%	4226
2021 Q2	$2K	Hold	323	–	–	﹤0.01%	4140
2021 Q1	$2K	Buy	+323	New	+$1.79K	﹤0.01%	4006
2020 Q4	–	Sell	-50	Closed	–	–	3393
2020 Q3	$0	Sell	50 -250	-83%	-$1.07K	﹤0.01%	3039
2020 Q2	$1K	Buy	+300	New	+$1.24K	﹤0.01%	2681

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

CAPTRUST Financial Advisors's AMRX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Amneal Pharmaceuticals (AMRX) stake by 10% in Q2 2026, buying an estimated $14.9K and bringing the position to 11,845 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

CAPTRUST Financial Advisors first reported a position in AMRX in Q2 2020 and has held it in 11 quarters since. The position peaked at $233K in Q1 2022. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

CAPTRUST Financial Advisors held 11,845 shares of Amneal Pharmaceuticals worth $205K as of Q2 2026.
CAPTRUST Financial Advisors bought 1,089 Amneal Pharmaceuticals shares in Q2 2026, an estimated $14.9K.
Amneal Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2872 holding.
CAPTRUST Financial Advisors first reported a position in Amneal Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
CAPTRUST Financial Advisors's Amneal Pharmaceuticals position peaked at $233K in Q1 2022.
306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.